Voglibose

Voglibose	
	
Clinical data	
AHFS/Drugs.com	International Drug Names
ATC code	A10BF03 (WHO)
Identifiers	
IUPAC name[show]	
CAS Number	83480-29-9 ✓
PubChem CID	444020
DrugBank	DB04878 ✓
ChemSpider	392046 ✓
UNII	S77P977AG8
KEGG	D01665 ✓
ChEMBL	CHEMBL476960 ✓
Chemical and physical data	
Formula	$C_{10}H_{21}NO_7$
Molar mass	267.28 g/mol
3D model (JSmol)	Interactive image
SMILES[show]	

InChI[show]
(verify)

Voglibose (INN and USAN, trade name **Voglib**, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was first launched in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.[1]

Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.

There are three drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest.

References^

https://www.takeda.com/news/2008/20080526_3621.html